How would you treat a patient with high-volume metastatic prostate cancer who has asymptomatic biochemical relapse after having a good response to upfront docetaxel?

If the patient is asymptomatic or minimally symptomatic and now castrate-resistant, I would start with sipuleucel-T. Based on the PSA quartile data (Schellhammer et al 2013) and in line with current NCCN guidelines and supportive clinical and preclinical data, immunotherapy should be used as early a...